เดือน: มีนาคม 2026

KAWASAKI, Japan, Mar 23, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced that its comprehensive traffic simulation system, developed under contract for the Ministry of Land, Infrastructure, Transport and Tourism (MLIT)-led regional transportation DX promotion project COMmmmONS, has been adopted for the Maebashi City Regional Public Transportation Plan, published by the local government on March 23, 2026. Analysis carried out by the system is included in the plan as scientific evidence supporting the policy to increase bus routes, one of the plan's key measures.Across municipalities nationwide, addressing the needs of transportation-disadvantaged residents and responding to carbon neutrality in the transportation sector have become urgent challenges, driving the need to advance and modernize public transportation systems.In Maebashi City, challenges such as demographic changes, increasingly diverse mobility needs, and a shortage of bus drivers have emerged. As the city examined optimal bus route reorganization measures under the Maebashi City Regional Public Transportation Plan, it required robust and credible scientific evidence to substantiate the effectiveness of these measures.Fujitsu was selected for the COMmmmONS project in April 2025 and developed a system capable of simulating both fixed-route and demand-responsive transportation, a first for Japan. The utility of the simulation results generated by this system was subsequently recognized, leading to its adoption in Maebashi City's regional public transportation plan.The comprehensive traffic simulation system leverages Fujitsu's social digital twin technology to support the pre-verification of measures by simulating human and social behavior. It utilizes generally available statistical data on resident attributes, movement, and destinations, as well as ridership data obtainable from MaaS apps.1. Evaluation of policy effects through high-precision simulationThe system utilizes unique Fujitsu technologies: artificial population technology, which generates resident data reflecting regional characteristics based on over 10 statistical anonymized datasets including the National Census; a behavioral selection model that uses AI to learn real-world travel data (i.e., travel times, costs for potential routes, residents' ages, car ownership status, etc.) and reproduce the travel mode selection characteristics of local residents; and multi-agent simulation technology, capable of simulating multiple transportation modes with different characteristics. This enables the estimation of detailed resident travel demand and generates simulation results that closely reflect real-world travel conditions, even when actual travel data is insufficient, thereby accurately evaluating the expected effects of policies.2. Streamlining plan formulation and accelerating consensus buildingThe system handles travel demand forecasting and modal split estimation as well as policy consideration and visualization of simulation results. Utilizing this system in regional transportation plan formulation can streamline the process, reducing the time required for consensus building with stakeholders, particularly transportation operators, by approximately 25%. The process previously could take between one and two years when outsourced to consulting firms.3. Support for optimal plan formulation with multi-faceted evaluation indicatorsThe system provides a wide range of evaluation indicators, including usage status and service levels for each transportation mode, ride-sharing rates for demand-responsive transport, and overall project costs for measures. This enables a comprehensive evaluation of the impact of transportation policies on users, operators, and the entire region, supporting the formulation of optimal plans to resolve "transportation deserts" where securing public transportation is difficult, and to realize sustainable regional transportation.Fujitsu plans to commercialize this system as a service by fiscal year 2026, developing it into a standard tool applicable across Japan. It will also promote collaboration with partners engaged in optimizing regional transportation, including local governments, consulting firms, and transportation operators. Through these efforts, Fujitsu aims to support the formulation of regional public transportation plans for local governments across Japan.Fujitsu will continue to train the system using mobility data and other sources to establish it as an AI engine capable of accurately replicating the diverse behaviors of local residents so that it can contribute to urban development and community planning nationwide.Under Uvance, Fujitsu's business model to address societal challenges, it will advance sustainable cities where everyone can live comfortably by enhancing regional transportation through data and AI.About COMmmmONSIn the field of regional transportation, while the adoption of digital technologies such as MaaS and ride-hailing apps is progressing, the siloed development of business models and systems has resulted in a lack of interoperability between services and data. As improving the quality and productivity of transportation services to resolve transportation deserts becomes an urgent issue, a new approach is needed to systematically promote regional transportation DX centered on collaboration and cooperation. The regional transportation DX promotion project "COMmmmONS (Code for Mobility Common Society)" is a new initiative that aims to create and standardize best practices for problem-solving using digital technology across four pillars: services, data, management, and business processes. By horizontally deploying these practices, it seeks to create technological assets that become common property for society.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Mar 23, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE:6501) announced that it has been named a 2026 Catalyst Award winner , in recognition of its efforts to embed inclusion as a core element of its global management and business strategies.Catalyst is the global nonprofit accelerating organizational performance and progress through workplace inclusion for everyone. The Catalyst Award is the premier global recognition of workplace inclusion initiatives.Through the “Together, We Are Stronger” initiative, Hitachi has driven a more inclusive culture across the organization by advancing inclusive leadership and strengthening talent practices while addressing long-established cultural norms in Japan. Championed by senior leadership, Hitachi’s approach combines global governance with local implementation to accelerate talent opportunities across the company’s diverse markets, while promoting a culture of psychological safety, trust and shared accountability. The initiative focuses on leadership development programs at multiple career stages, transparent talent processes, and company‑wide well‑being efforts that support all employees. Together, these efforts demonstrate how inclusion can drive both organizational performance and innovation, positioning Hitachi as a company committed to delivering social and business impact.Lorena Dellagiovanna, Senior Vice President and Executive Officer, CHRO, Chief Sustainability Officer , Hitachi, Ltd. , said: Inclusion is how we build strong teams and better ideas at Hitachi. When people have fair opportunity to contribute and grow, innovation follows and drives positive social impact. This Catalyst Award affirms the journey we have taken and reinforces our commitment to keep moving forward.For more information about Hitachi Group’s inclusion initiative, please visit: Hitachi Sustainability Report 2025About Catalyst: https://www.catalyst.org/Catalyst Press Release:https://www.catalyst.org/about/newsroom/2026/media-release-2026-catalyst-awardAbout Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY 2024 (ended March 31, 2025) totaled 9,783. 3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and CAMBRIDGE, Mass., Mar 23, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that new real‑world findings from an analysis of long‑term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanemab (generic name, brand name LEQEMBI®), an anti‑amyloid‑β (Aβ) protofibril antibody, showed that most patients continue with ongoing lecanemab therapy after the initial 18 months of treatment. The analysis was presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark, and online.In real‑world clinical practice, patients with chronic diseases who stay on their treatments longer tend to experience better clinical outcomes and higher satisfaction.1,2 Ninety-four percent of patients who completed 18 months of lecanemab treatment in the Phase III Clarity AD chose to continue maintenance treatment by enrolling in the subsequent open-label, long-term extension (OLE) study. In the OLE of Clarity AD study, patients continue to benefit from four years of lecanemab treatment compared with the natural course of Alzheimer’s disease (Alzheimer’s Disease Neuroimaging Initiative: ADNI*).Long-Term Persistence and Patient Characteristics for Lecanemab in Real-World Use in the United States (Presentation: March 20, 17:05 CET)This analysis is the first time real-world lecanemab data on treatment persistence beyond 18 months has been reported.This study was a retrospective observational analysis using the PurpleLab® CLEAR Claims database, a comprehensive dataset based on medical insurance claims across the United States and was conducted to evaluate the long‑term treatment persistence of lecanemab in real‑world clinical practice.Patient background and dosing The analysis population consisted of 10,763 individuals who met the requirement for continuous healthcare encounters, out of the 13,388 individuals recorded in the database who received at least one intravenous treatment with lecanemab between January 6, 2023 and November 30, 2025. At baseline, the mean age was 73.8 years and 56.5% were female. The most common comorbidities were dyslipidemia (42.2%) and hypertension (36.9%). The mean follow-up duration was 350.9 days. The average number of administrations was 1.7 per month, and the mean dosing interval was 16.4 days (median 14 days), which was generally consistent with the recommended every two weeks dosing.Long-Term persistence results The time-dependent proportion of patients who remained on lecanemab treatment was evaluated, using the Kaplan–Meier method in a subgroup of 371 patients who initiated treatment in 2023 and had 20 months of continuous follow-up, thereby enabling assessment of long-term treatment persistence beyond 18 months. As a result, 78.4% of individuals continued lecanemab treatment at 18 months, 71.7% at 20 months, and 67.3% at 24 months. Of the 78.4% of patients who remained on lecanemab at 18 months, the majority of them continued treatment during the maintenance period beyond 18 months, confirming a high rate of treatment persistence with lecanemab in real-world clinical practice. The patient characteristics and dosing patterns observed in this claims-based analysis were generally similar to those reported in the Clarity AD. Furthermore, the relatively high treatment adherence observed among individuals suggests that potential delays due to MRI monitoring requirements, adverse events, and other factors did not substantially affect lecanemab dosing.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.* ADNI is a clinical research project launched in 2005 to develop methods to predict the onset and progression of AD and to confirm the effectiveness of treatments. The project involves a multi-year longitudinal observation targeting healthy elderly individuals as well as patients with mild cognitive impairment (MCI) and early stages of AD.About lecanemab (generic name, brand name: LEQEMBI)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 10 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.In the global Phase 3 placebo-controlled, double-blind, parallel-group, randomized Clarity AD core study, the mean change from baseline between the lecanemab treated group and the placebo group after 18 months was -0.45 (P=0.00005) on the primary endpoint of CDR-SB global cognitive and functional scale. To provide context, a change from 0.5 to 1 on the Clinical Dementia Rating (CDR) score domains of Memory, Community Affairs and Home/Hobbies reflects a shift from mild impairment to loss of independence. This can affect a person’s ability to be left alone safely, recall recent events, participate in daily activities, manage household tasks, and engage in hobbies and intellectual interests.3,4Over three years of treatment, including both the core study and the OLE, data showed lecanemab demonstrated a reduction in cognitive decline—measured by CDR-SB—of 1.01 points compared to the expected decline observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort. This benefit grew more pronounced after four years, with a reduction of 1.75 points. Similarly, when benchmarked against the expected decline in the BioFINDER** cohort, lecanemab showed a reduction of 1.40 points at three years and an even greater reduction of 2.17 points at the four years mark.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.** BioFINDER subjects are similar to Study 301 and ADNI subjects, except all BioFINDER subjects are in the MCI stage and no mild AD subjects are included, and their baseline CDR-SB is lower. BioFINDER is a largescale, long-term prospective study led by Lund University in Sweden, aiming to establish early. diagnosis and elucidate pathophysiology of neurodegenerative diseases. In addition to AD, the study also focuses on conditions including Parkinson's Disease. Individuals participating in the study undergo regular clinical assessments, cognitive function tests, brain imaging (MRI, Aβ PET, Tau PET), and collection of biomarkers from blood and cerebrospinal fluid (CSF).About ProtofibrilsProtofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.3 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.4About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTubeMEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.(Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 7739-600-678EMEA-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@Eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.comBiogen Safe HarborThis news release contains forward-looking statements, including about the potential clinical effects of lecanemab (marketed as LEQEMBI); the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for LEQEMBI (lecanemab) subcutaneous autoinjector (SC-AI); the potential to expand options and reduce healthcare resources by treating Alzheimer's disease at home; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.Digital Media DisclosureFrom time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.References(1) Guerci B et al. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Therapy, 2019; 10(2), 437-449.(2) Menditto E et al. Persistence as a robust indicator of medication adherence-related quality and performance. International journal of environmental research and public health, 2021; 18(9), 4872.(3) Cohen S., et al. J Prev Alzheimers Dis.2022;9(3):507-522.(4) Morris JC. Neurology. 1993;43(11):2412-4.(5) Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021; 12:3451. doi:10.1038/s41467-021-23507-z(6) Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Singapore and Taipei, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - AEM Holdings Ltd. (“AEM” or “the Group”), a global leader in test innovation, announced a strategic partnership with ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX) (“ASE”), the leading provider of semiconductor assembly, testing and materials (“ATM”) services and the provider of electronic manufacturing (“EMS”) services. The collaboration brings together AEM’s proprietary test technologies with ASE’s world-class manufacturing scale to deliver disruptive test solutions tailored for the rapidly expanding Artificial Intelligence (“AI”) and High-Performance Computing (“HPC”) markets.Aligned with the strategic partnership, AEM will raise approximately S$12 million in gross proceeds through a private placement of 3,350,000 million ordinary shares to a wholly owned subsidiary of ASE, representing 1.06% of AEM’s issued share capital as at 21 March 2026, at an issue price of S$3.591 per share. ASE, through said subsidiary, will also receive a total of 28,111,856 million free detachable warrants, divided equally into two exercisable tranches, with each tranche subject to certain ASE-attributable revenue-related conditions. Each warrant is exercisable into one ordinary share, with the Tranche 1 exercise price set at 103% of the volume weighted average price (“VWAP”) of AEM’s shares for the full market day on which the subscription agreement is signed, and the Tranche 2 exercise price set at 105% ofsuch VWAP. If fully exercised, the warrants would result in an additional 8.935% of the current issued share capital. The transaction remains subject to certain conditions, including the approval of the Singapore Exchange for the listing and quotation of the new shares.Proceeds from the private placement will support AEM’s continued expansion in Taiwan and the joint integration of AEM’s test technologies, including highly parallel test architectures and advanced thermal management capabilities, into ASE’s manufacturing and test environments. The funds will also be used to advance AEM’s product roadmap, enhance its system offerings, and accelerate joint go to market initiatives aimed at supporting next generation AI and HPC applications.The strategic partnership also supports ISE Labs, a wholly owned subsidiary of ASE, as it expands AI and HPC processor development capabilities to address early-stage testing, validation, and characterization requirements. These efforts focus on heterogeneous integration architectures, including multi-chiplet and advanced system-in-package designs as well as optical interconnect technologies critical to next-generation compute platforms. ASE’s ATM portfolio further strengthens these initiatives with high-volume advanced packaging and test capabilities, enabling production-scale deployment as global demand continues to accelerate.Ken Hsiang, Chief Executive Officer of ISE Labs, stated: “As compute architectures grow more complex and time-to-production continues to compress, test has become a critical enabler of performance, reliability, and manufacturability for next-generation AI and HPC systems. By combining ISE’s advanced characterization and production-readiness capabilities with AEM’s scalable, high-parallel test technologies and system-level engineering strengths, this strategic partnership enables rapid transition from validation to ASE’s high-volume deployment while addressing the increasing complexity of advanced compute testing.”Samer Kabbani, Chief Executive Officer of AEM, commented, “This partnership represents an important step in AEM’s strategy to work closely with industry leaders to advance the state of AI and HPC testing. ASE’s forward-looking approach and global scale make them an ideal partner as test requirements continue to intensify across advanced compute platforms. By combining our respective strengths, we aim to develop and deploy next-generation test solutions that help customers improve performance, scalability, and time-to-market.”About ASE Technology Holding Co., Ltd.ASEH is the leading provider of semiconductor manufacturing services in assembly and test. The Company develops and offers complete turnkey solutions covering front-end engineering test, wafer probing and final test, as well as packaging, materials and electronic manufacturing services through USI with superior technologies, breakthrough innovations, and advanced development programs. With advanced technological capabilities and a global presence spanning Taiwan, China, South Korea, Japan, Singapore, Malaysia, Philippines, Vietnam, Mexico, and Tunisia as well as the United States and Europe, ASEH has established a reputation for reliable, high quality products and services. For more information, please visit our website at https://www.aseglobal.com.About AEMAEM is a global leader in test innovation. We provide the most comprehensive semiconductor and electronics test solutions based on the best-in-class technologies, processes, and customer support. AEM has a global presence across Asia, Europe, and the United States. AEM's R&D centres are situated in Singapore, Malaysia, Finland, France, and the US. With manufacturing plants located in Singapore, Malaysia (Penang), Indonesia (Batam), Vietnam, Finland (Lieto), South Korea, and the United States and a global network of engineering support, sales offices, associates, and distributors, we offer our customers a robust and resilient ecosystem of test innovation and support.AEM Holdings Ltd. is listed on the main board of the Singapore Exchange (Reuters: AEM. SI; Bloomberg: AEM SP). AEM’s head office is in Singapore.For more information please contact:Kamal SAMUEL / Rishika TIWARI / LIM En Tong Financial PR Pte LtdTel: 6438 2990 / Fax: 6438 0064E-mail: kamal@financialpr.com.sg / rishika@financialpr.com.sg / entong@financialpr.com.sgPatricia MacLeod ASE, Inc.Tel: +1 408 314 9740E-mail: patricia.macleod@aseus.com Safe Harbor Notice (ASE)This press release contains "forward-looking statements" within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although these forward-looking statements, which may include statements regarding our future results of operations, financial condition or business prospects, are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to us, are intended to identify these forward-looking statements in this press release. These forward-looking statements are necessarily estimates reflecting the best judgment of our senior management and our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied by the forward-looking statements for reasons including, among others, risks associated with cyclicality and market conditions in the semiconductor or electronic industry; changes in our regulatory environment, including our ability to comply with new or stricter environmental regulations and to resolve environmental liabilities; demand for the outsourced semiconductor packaging, testing and electronic manufacturing services we offer and for such outsourced services generally; the highly competitive semiconductor or manufacturing industry we are involved in; our ability to introduce new technologies in order to remain competitive; international business activities; our business strategy; our future expansion plans and capital expenditures; the strained relationship between the Republic of China and the People’s Republic of China; general economic and political conditions; the recent shift in United States trade policies; possible disruptions in commercial activities caused by natural or human-induced disasters; fluctuations in foreign currency exchange rates; and other factors. The announced results of the full year of 2025 are preliminary and subject to audit adjustments. For a discussion of these risks and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including the 2024 Annual Report on Form 20-F filed on March 27, 2025.Disclaimer (AEM)This is a press release of general information relating to the current activities of AEM Holdings Ltd. (“AEM”). It is given in summary form and does not purport to be complete. This press release may contain forward-looking statements which are subject to risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in these forward-looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other companies, shifts in customer demands, customers and partners, changes in operating expenses, governmental and public policy changes, and the continued availability of financing. Accordingly, such statements are not and should not be construed as a representation as to the future of AEM, and are not intended to be profit forecasts, estimations or projections of future performance and should not be regarded as such. No reliance should therefore be placed on these forward-looking statements, which are based on the current views of the management of AEM. The press release is also not to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. AEM accepts no responsibility whatsoever with respect to the use of this document or any part thereof. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com